View in EDS

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.

Saved in:
Bibliographic Details
Title: A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.
Authors: Roberts TJ; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA., Meador CB; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA., Fuld AD; Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA., Lasko A; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA., Frigault M; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA., Hangar KM; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA., Reynolds K; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA., Sadow PM; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA., Wirth LJ; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.
Source: Thyroid : official journal of the American Thyroid Association [Thyroid] 2026 Jun; Vol. 36 (6), pp. 682-687. Date of Electronic Publication: 2026 May 12.
Publication Type: Journal Article; Case Reports
Journal Info: Publisher: Mary Ann Liebert Publishers Country of Publication: United States NLM ID: 9104317 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-9077 (Electronic) Linking ISSN: 10507256 NLM ISO Abbreviation: Thyroid Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42117355
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Roberts+TJ%22">Roberts TJ</searchLink>; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Meador+CB%22">Meador CB</searchLink>; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Fuld+AD%22">Fuld AD</searchLink>; Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.<br /><searchLink fieldCode="AU" term="%22Lasko+A%22">Lasko A</searchLink>; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Frigault+M%22">Frigault M</searchLink>; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hangar+KM%22">Hangar KM</searchLink>; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Reynolds+K%22">Reynolds K</searchLink>; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Sadow+PM%22">Sadow PM</searchLink>; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Wirth+LJ%22">Wirth LJ</searchLink>; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229104317%22">Thyroid : official journal of the American Thyroid Association</searchLink> [Thyroid] 2026 Jun; Vol. 36 (6), pp. 682-687. <i>Date of Electronic Publication: </i>2026 May 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Case Reports
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mary+Ann+Liebert+Publishers%22">Mary Ann Liebert Publishers </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9104317 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-9077 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210507256%22">10507256 </searchLink><i>NLM ISO Abbreviation: </i>Thyroid <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42117355
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/10507256261448706
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 682
    Titles:
      – TitleFull: A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Roberts TJ
      – PersonEntity:
          Name:
            NameFull: Meador CB
      – PersonEntity:
          Name:
            NameFull: Fuld AD
      – PersonEntity:
          Name:
            NameFull: Lasko A
      – PersonEntity:
          Name:
            NameFull: Frigault M
      – PersonEntity:
          Name:
            NameFull: Hangar KM
      – PersonEntity:
          Name:
            NameFull: Reynolds K
      – PersonEntity:
          Name:
            NameFull: Sadow PM
      – PersonEntity:
          Name:
            NameFull: Wirth LJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1557-9077
          Numbering:
            – Type: volume
              Value: 36
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Thyroid : official journal of the American Thyroid Association
              Type: main
ResultId 1